Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Blood (2024) 143 (16): 1599–1615.

https://doi.org/10.1182/blood.2023021570

Published: 2024

Includes: Supplemental data

Journal Articles

CD38-Directed, Single-Chain T Cell-Engager Targets Leukemia Stem Cells through IFNγ-Induced CD38 Expression

Blood (2023) 142 (Supplement 1): 2797.

https://doi.org/10.1182/blood-2023-189901

Published: 2023

Journal Articles

Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3296.

https://doi.org/10.1182/blood-2023-190157

Published: 2023

Journal Articles

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Lawrence Liu, Scott R. Goldsmith, Sheryl Leahey, Carlos Gomez Luna, Shawn Streeter, Adam Braun, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Azra Borogovac, Jonathan Keats, Myo Htut, Arnab Chowdhury, Sanjeet Singh Dadwal, Amrita Krishnan, Murali Janakiram

Blood (2023) 142 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2023-188077

Published: 2023

Journal Articles

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Ajai Chari, Albert Oriol, Amrita Krishnan, Maria Del Carmen Martinez Chamorro, Luciano Costa, Maria Victoria Mateos, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, M. Damiette Smit, Swarna Ramanjulu, Paula Rodríguez Otero

Blood (2023) 142 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2023-181228

Published: 2023

Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2023-182330

Published: 2023

Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Blood (2023) 142 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2023-184710

Published: 2023

Journal Articles

Impact of Health Insurance and Access to Autologous Stem Cell Transplantation (ASCT) on Racial Inequity in Overall Survival (OS) Among Patients with Multiple Myeloma (MM)

F. Lennie Wong, Scott R. Goldsmith, Kimlin Ashing, Amrita Krishnan, Michael Rosenzweig, Saro Armenian

Blood (2023) 142 (Supplement 1): 4730.

https://doi.org/10.1182/blood-2023-174296

Published: 2023

Journal Articles

Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia

Robert Allen Vescio, Yuliya Linhares, Ryan Ponec, Christopher Lopiccolo, Amanda Park, Rhona Castillo, Amrita Krishnan

Blood (2023) 142 (Supplement 1): 7057.

https://doi.org/10.1182/blood-2023-181957

Published: 2023

Journal Articles

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Ahmad H. Mattour, MD, Leslie L. Popplewell, MD FACP, Charalambos Andreadis, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Jonah Shulman, MD, Sudhir Manda, MD, John M. Burke, MD, Saurabh Chhabra, MD, Jeff P Sharman, MD, Amrita Krishnan, MD, Nina Shah, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, MBA, Craig Jerome Berman, MD, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139829

Published: 2020

Journal Articles

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Jesus G. Berdeja, MD, Albert Oriol, Niels W. C. J. van de Donk, MD, Paula Rodriguez, Elham Askari, Maria-Victoria Mateos, MD PhD, Monique C. Minnema, MD PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Thomas Prior, Brandi W. Hilder, PhD, Jeffery Russell, MD PhD, Jenna D. Goldberg, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-133873

Published: 2020

Journal Articles

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Amrita Krishnan, MD, Rafael Fonseca, MD, Peter A Forsberg, MD, Andrew Spencer, Jesus G. Berdeja, MD, Jacob P. Laubach, MD, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M Fine, Suzanne Trudel

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136985

Published: 2020

Journal Articles

Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Amrita Krishnan, MD, Antje Hoering, PhD, Parameswaran Hari, MD MRCP, Rachael Sexton, PhD, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142913

Published: 2020

Journal Articles

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Alfred L. Garfall, MD, Saad Z. Usmani, MDMBBS,MBA, María-Victoria Mateos, Hareth Nahi, MD PhD, Niels W.C.J. van de Donk, MD PhD, Jesus F. San-Miguel, MD PhD, Albert Oriol Rocafiguera, MD, Laura Rosinol, MD PhD, Ajai Chari, MD, Manisha Bhutani, MD, Lixia Pei, PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Tara Stephenson, PhD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-138831

Published: 2020

Journal Articles

Immune Mediated Mechanisms of Resistance to Daratumumab

Domenico Viola, Ada Dona, Emine Gulsen Gunes, PhD, Estelle Troadec, Xiwei Wu, Sergio Branciamore, Tinisha McDonald, MS, Lucy Ghoda, PhD, Ashish Streatfield, James F Sanchez, PhD, Chatchada Karanes, Myo Htut, Michael Rosenzweig, Jonathan J Keats, PhD, Steven T Rosen, Guido Marcucci, Amrita Krishnan, MD, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2018-99-117441

Published: 2018

Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

Michael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, MD, Flavia Pichiorri, PhD, Firoozeh Sahebi, Tim Synold, Xiwei Wu, James F Sanchez, Amrita Krishnan, MD, Stephen J Forman, Steven T Rosen

Blood (2018) 132 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2018-99-120042

Published: 2018

Journal Articles

CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Emine Gulsen Gunes, PhD, Hadas Lewinsky, Domenico Viola, Enrico Caserta, Michael Rosenzweig, Myo Htut, James F Sanchez, PhD, Ralf Buettner, PhD, Guido Marcucci, Jonathan J Keats, PhD, Amrita Krishnan, MD, Steven T Rosen, Idit Shachar, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2018-99-119655

Published: 2018

Journal Articles

Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses

Xu Steven Xu, Philippe Moreau, Saad Z. Usmani, MD, Sagar Lonial, MD, Andrzej Jakubowiak, MD PhD, Albert Oriol, MD, Amrita Krishnan, MD, Joan Bladé, MD PhD, Melody Luo, PhD, Yu-Nien Sun, PhD, Liping Zhang, William Deraedt, Ming Qi, MD PhD, Jon Ukropec, PhD, Pamela L Clemens, PhD

Blood (2018) 132 (Supplement 1): 1970.

https://doi.org/10.1182/blood-2018-99-113171

Published: 2018

Journal Articles

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Blood (2018) 131 (7): 741–745.

https://doi.org/10.1182/blood-2017-09-807263

Published: 2018

Includes: Multimedia, Supplemental data

Journal Articles

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Blood (2017) 130 (Supplement 1): 395.

https://doi.org/10.1182/blood.V130.Suppl_1.395.395

Published: 2017

NARROW

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

CD38-Directed, Single-Chain T Cell-Engager Targets Leukemia Stem Cells through IFNγ-Induced CD38 Expression

Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Impact of Health Insurance and Access to Autologous Stem Cell Transplantation (ASCT) on Racial Inequity in Overall Survival (OS) Among Patients with Multiple Myeloma (MM)

Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Immune Mediated Mechanisms of Resistance to Daratumumab

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only